Status:
COMPLETED
Feasibility, Acceptability, and Preliminary Effects of Lymfit
Lead Sponsor:
McGill University
Collaborating Sponsors:
Jewish General Hospital
McGill University Health Centre/Research Institute of the McGill University Health Centre
Conditions:
Cancer Survivors
Lymphoma
Eligibility:
All Genders
18-39 years
Phase:
NA
Brief Summary
Background: Lymphoma is one of the most diagnosed cancers in young adults aged 18 to 39. Lymphoma is highly treatable, and the survival rate is often high. Yet, cancer treatments can be toxic, and the...
Detailed Description
Background: Lymphoma and its subtypes are among the most commonly diagnosed cancers in young adults aged 18 to 39. Most types of lymphoma are often treated with curative therapies. Unfortunately, trea...
Eligibility Criteria
Inclusion
- Newly diagnosed lymphoma patients who received an initial diagnosis at the age of 18 to 39
- Receiving or have received chemotherapy with curative intent within the past six months
- Own a smartphone that is able to download the Fitbit application
- Have an internet connection at home that supports participation in coaching sessions via videoconferencing and the ability to complete the study questionnaires online
- Proficient in either French or English
Exclusion
- 1\) Have any contra-indications to moderate to vigorous levels of exercise
Key Trial Info
Start Date :
February 1 2022
Trial Type :
INTERVENTIONAL
Allocation :
ACTUAL
End Date :
December 1 2023
Estimated Enrollment :
26 Patients enrolled
Trial Details
Trial ID
NCT05259657
Start Date
February 1 2022
End Date
December 1 2023
Last Update
April 5 2024
Active Locations (1)
Enter a location and click search to find clinical trials sorted by distance.
1
Jewish General Hospital
Montreal, Quebec, Canada, H3A 2A7